Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) has been assigned an average rating of “Hold” from the nineteen analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, thirteen have issued a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $6.57.
Several research analysts have recently weighed in on FATE shares. Wells Fargo & Company dropped their price target on shares of Fate Therapeutics from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 9th. Morgan Stanley dropped their price objective on Fate Therapeutics from $5.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, November 13th. Mizuho cut their price target on Fate Therapeutics from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, November 20th. Cantor Fitzgerald reiterated a “neutral” rating and set a $5.00 price objective on shares of Fate Therapeutics in a report on Thursday, September 7th. Finally, Wedbush reissued a “neutral” rating and set a $3.00 price objective (down from $6.00) on shares of Fate Therapeutics in a report on Thursday, November 9th.
Check Out Our Latest Stock Analysis on FATE
Hedge Funds Weigh In On Fate Therapeutics
A number of hedge funds have recently modified their holdings of the business. American Century Companies Inc. boosted its holdings in Fate Therapeutics by 74.7% in the third quarter. American Century Companies Inc. now owns 37,062 shares of the biopharmaceutical company’s stock valued at $79,000 after purchasing an additional 15,848 shares during the period. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Fate Therapeutics by 2.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,389,123 shares of the biopharmaceutical company’s stock valued at $5,065,000 after acquiring an additional 54,005 shares in the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of Fate Therapeutics by 14.7% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 154,178 shares of the biopharmaceutical company’s stock valued at $327,000 after purchasing an additional 19,775 shares in the last quarter. GSA Capital Partners LLP boosted its position in shares of Fate Therapeutics by 30.4% in the 3rd quarter. GSA Capital Partners LLP now owns 253,429 shares of the biopharmaceutical company’s stock worth $537,000 after buying an additional 59,019 shares in the last quarter. Finally, Laurion Capital Management LP lifted its position in Fate Therapeutics by 128.6% during the third quarter. Laurion Capital Management LP now owns 35,173 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 19,787 shares during the period.
Fate Therapeutics Stock Performance
FATE opened at $3.15 on Tuesday. The stock has a market capitalization of $310.59 million, a PE ratio of -1.78 and a beta of 1.57. The stock’s 50 day moving average price is $2.24 and its 200-day moving average price is $3.17. Fate Therapeutics has a 52-week low of $1.63 and a 52-week high of $13.15.
Fate Therapeutics (NASDAQ:FATE – Get Free Report) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.13. Fate Therapeutics had a negative net margin of 163.04% and a negative return on equity of 38.44%. The company had revenue of $1.94 million during the quarter, compared to analyst estimates of $0.99 million. Research analysts forecast that Fate Therapeutics will post -1.79 EPS for the current fiscal year.
About Fate Therapeutics (Get Free Report
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors.
Featured Stories
NASDAQ: FATE” width=”600″ height=”385″ loading=”lazy”>
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Fate Therapeutics, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Fate Therapeutics wasn’t on the list.
While Fate Therapeutics currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.